Latest news with #BioLineRxLtd
Yahoo
30-05-2025
- Business
- Yahoo
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
BioLineRx Ltd's (NASDAQ:BLRX) poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 American Society of Clinical Oncology Annual Meeting. The CheMo4METPANC trial is evaluating motixafortide, cemiplimab, and standard-of-care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC). Updated results from the pilot phase indicate that four of eleven patients remained progression-free after more than one patients underwent definitive treatment for mPDAC: one had complete resolution of all radiologically detected liver lesions and underwent definitive radiation to the primary pancreatic tumor, and one had a sustained partial response and underwent pancreaticoduodenectomy with pathology demonstrating a complete response. An analysis of pre-and-on-treatment biopsies and peripheral blood mononuclear cells (PBMCs) also revealed that CD8+ T-cell tumor infiltration increased across all eleven patients treated with the motixafortide combination. In addition, patients achieving a partial response were found to have higher pre-treatment proportions of CXCL12-producing cancer-associated fibroblasts, a potential marker of response. The pilot clinical trial of motixafortide, cemiplimab, gemcitabine and nab-paclitaxel (N=11) demonstrated an overall response rate (ORR) of 64% (7/11) and a disease control rate (DCR) of 91% (10/11), compared to historical ORR and DCR of 23% and 48%, respectively, with gemcitabine and nab-paclitaxel. Based on these results, the CheMo4METPANC Phase 2 trial was amended to become a randomized study, with planned enrollment increasing from 30 to 108 patients. The trial is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies. The trial will be fully enrolled in 2027, and a prespecified interim analysis is planned for when 40% of PFS events are observed. Earlier this week, BioLineRx said it reduced operating expense run rate by over 70% beginning January 1, 2025, through the APHEXDA program transfer to Ayrmid and the resulting shutdown of the company's U.S. commercial operations in Q4 2024, as well as additional headcount and other operating expense reductions. The company completed financing in January 2025, raising gross proceeds of $10 million and reaffirmed cash runway through the second half of 2026. Jones Trading upgraded BioLine Rx from Hold to Buy and announced a $12 price target. Price Action: BLRX stock is up 42.7% at $5.41 at the last check on Friday. Read Next:Photo by jittawit21 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? BIOLINE RX (BLRX): Free Stock Analysis Report This article Why Is Nano-Cap BioLineRx Stock Surging On Friday? originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
20-05-2025
- Business
- Yahoo
BioLineRx to Report First Quarter 2025 Results on May 27, 2025
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2025 on Tuesday, May 27, 2025, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until May 29, 2024; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally. About BioLineRx BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's first approved product is APHEXDA® (motixafortide), with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally, excluding Asia) and Gloria Biosciences (in Asia). BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs, manufacturing and commercialization to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to the bedside. Learn more about who we are, what we do, and how we do it at or on Twitter and LinkedIn. and events. Logo: Contacts: United StatesIrina KofflerLifeSci Advisors, LLCIR@ IsraelMoran MeirLifeSci Advisors, LLCmoran@ View original content to download multimedia: SOURCE BioLineRx Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
